Well-directed post, Skorogi. Prurisol is an important part of the company's profile and its assets – a bit more, IMO, than merely a "side show", at least at this stage of Kevetrin's development. All the preliminary and interim data on Kevetrin have, in any case, been promising and encouraging. If your time-frame of " one week or less" for an update is correct, this is the right time for prospective shareholders to consider taking up a position. The price action on Thursday could turn out to be a good predictor of what will happen this week.